Martin Bonde leaves consultancy firm for CEO position in Swiss company

Experienced biotech leader Martin Bonde leaves Danish Novo Seeds' consultancy firm Biorigin to become CEO of a Swiss cancer company, where Novo Seeds is also a major investor. "I just had to accept," he says.

Sebastian Buur Gunvald/Jyllands-Posten/Ritzau Scanpix
Photo: Sebastian Buur Gunvald/Jyllands-Posten/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles